LC-MS Immunocapture for Precise ADA Isotyping and Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods are inadequate for accurately characterizing and quantifying anti-drug antibodies (ADAs) induced by pharmaceutical products, which affect drug efficacy and safety, due to the biological complexity of immune responses and limited understanding of their pharmacokinetic impacts.
Innovation Solution
The use of immunocapture and Liquid Chromatography-Mass Spectrometry (LC-MS) methods for isotyping and quantifying ADAs, involving solid support attachment, mobile phase washing, enzymatic digestion, and mass spectrometry analysis to identify and quantify specific peptide sequences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to detect ADAs, then the detection process is simpler, but the measurement precision and reliability of ADA characterization is insufficient
Solution Approach 1:
The detection method is segmented into distinct functional modules: immunocapture module for selective ADA enrichment, liquid chromatography module for separation, and mass spectrometry module for identification and quantification. This segmentation allows each module to be optimized independently while maintaining overall system precision.
Solution Approach 2:
An immunocapture step using drug-specific antibodies is introduced as an intermediary between sample collection and analysis. This intermediary selectively enriches ADAs from complex biological matrices, significantly improving measurement precision by concentrating the target analyte and removing interfering substances.
2Loss of information
If comprehensive ADA characterization is performed, then the understanding of immunogenicity impacts improves, but the difficulty of detecting and measuring increases
Solution Approach 1:
The mass spectrometry platform is configured with multi-functionality to perform multiple characterization tasks simultaneously: identifying ADA presence, determining isotype classification, quantifying antibody levels, and analyzing binding characteristics. This universal approach comprehensively captures immunogenicity information without requiring separate specialized assays.
Solution Approach 2:
The immunocapture step performs preliminary enrichment and classification of ADAs before the main analysis. By pre-concentrating target antibodies and pre-classifying them by isotype, this preliminary action reduces the complexity of subsequent detection and measurement steps.
3Measurement precision
If quantitative analysis of ADAs is performed, then the pharmacokinetic impact assessment improves, but the measurement precision requirements increase
Solution Approach 1:
The immunocapture step serves as a preliminary concentration mechanism that enriches ADAs from dilute biological samples. This pre-concentration enables accurate quantification of low-abundance antibodies while maintaining precision across a wide concentration range through standardized enrichment protocols.
Solution Approach 2:
The system utilizes parameter changes in the mass spectrometry detection, including multiple reaction monitoring (MRM) transitions and quantification of specific peptide fragments, to achieve high precision quantification. By monitoring multiple transition pairs and using internal standards, the system maintains precision across varying ADA concentrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides precise and consistent identification and quantification of ADA isotypes, enabling better understanding of immunogenicity impacts on drug efficacy and safety, suitable for preclinical and clinical studies.
Implementation Method 1
contacting the sample to a solid support, wherein at least one pharmaceutical product has been attached to the solid support
Implementation Method 2
washing the solid support using at least one mobile phase solution to provide at least one eluent
Implementation Method 3
identifying the components of the isolated peptide or protein using a mass spectrometer
Data Source
AI summary
The present invention provides methods and systems for isotyping and quantification of antibodies based on immunocapture and/or Liquid Chromatography-Mass Spectrometry (LC-MS) analysis. These antibodies are induced by the administration of pharmaceutical products. The immunocapture method comprises contacting samples with a solid support, wherein the pharmaceutical product has been cross-linked directly to the solid support. The MS analysis includes conducting peptide mapping, selecting unique peptides and fragment ions to generate MRM (multiple reaction monitoring) transitions, optimizing collision energy, and determining a LLOQ (lower limit of quantification).